title: Initial clinical experience with a rationally designed, genetically engineered recombinant human hemoglobin.
authors.affiliation: Somatogen, Inc., Boulder, CO 80301.
authors.forename: S A
authors.initials: SA
authors.lastname: Shoemaker
authors.forename: M J
authors.initials: MJ
authors.lastname: Gerber
authors.forename: G L
authors.initials: GL
authors.lastname: Evans
authors.forename: L E
authors.initials: LE
authors.lastname: Archer-Paik
authors.forename: C H
authors.initials: CH
authors.lastname: Scoggin
mesh_terms: D000210:Acute-Phase Reaction / Q000209:etiology; D000818:Animals; D001802:Blood Substitutes / Q000009:adverse effects / Q000302:isolation & purification* / Q000627:therapeutic use*; D015195:Drug Design; D006454:Hemoglobins / Q000009:adverse effects / Q000235:genetics* / Q000627:therapeutic use*; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D010100:Oxygen / Q000378:metabolism; D015202:Protein Engineering; D011994:Recombinant Proteins / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use
chemical_list: D001802:Blood Substitutes; D006454:Hemoglobins; D011994:Recombinant Proteins; D010100:Oxygen